← Eichor
Study identifier: NCT06807606 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Condition: Hematologic Malignancies  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 2
Planned participants35
Who can joinAll sexes, N/A to 60 Years
Healthy volunteersNo

About this study

The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.

This description comes directly from the study's public registry record.

Talk to the study team

Warren Fingrut, MD  ·  713-745-2214  ·  wbfingrut@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06807606